On Friday, FDA published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage. APC leaders had met with FDA officials in advance of the agency’s issuing this emergency guidance to brief them on what would be needed for compounders to help fill gaps and meet local needs.
We believe some sterile compounding pharmacies may be able to help meet the needs of smaller, local hospitals in a limited but important way. (Limited because not all 503A pharmacies are able to prepare these kinds of IV bags because of the complexity involved, but those that can will be able to provide some support to local hospitals.)
That’s why, following the release of the temporary guidance, we gave FDA some practical suggestions that could better equip those 503As to help:
One of the most pressing challenges is the lack of available SWFI as a starting ingredient. We welcome your input on any additional suggestions or experiences you may have regarding this issue.
We’ll keep you informed as we continue our discussions with the FDA.